Q-omics provides the consensus-scored SNX12 profile across patient tissues and cancer cell-line models. SNX12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SNX12 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SNX12 protein abundance shows 22,404 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, and PDAC as cancer lineages where SNX12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX12 survival associations across molecular data types. SNX12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX12 RNA expression–survival associations across cancer types. High SNX12 expression shows unfavorable associations in HNSC, UCEC, PAAD, BLCA and UVM, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SNX12 RNA expression.
This table summarizes SNX12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SNX12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX12 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LIHC, BRCA, CHOL and LUSC. The HNSC box plot shows higher SNX12 RNA expression in tumor versus normal tissue (log2 FC = +0.708, t-test p < 0.001).
This table shows molecular features associated with SNX12 in patient tissues and cancer cell lines. In patient samples, SNX12 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
